Treatment-Free Remission in CML Sustainable After Nilotinib

Approximately half of patients with chronic-phase CML who achieved a sustained deep molecular response with nilotinib were able to discontinue therapy and remain in treatment-free remission through 96 weeks.

Source: CancerNetwork - July 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia & Lymphoma News Source Type: news